Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI Substudy.

Mukul Sharma,Robert G. Hart,Eric E. Smith,Jacqueline Bosch,John W. Eikelboom,Stuart J. Connolly,Leanne Dyal,Kevin W Reeh,Amparo Casanova,Rafael Diaz,Patricio López-Jaramillo,Georg Ertl,Stefan Störk,Gilles R. Dagenais,Eva Lonn,Lars Rydén,Andrew Tonkin,John Varigos,Deepak L. Bhatt,Kelley R. Branch,Jeffrey L. Probstfield,Jae Hyung Kim,Martin ODonnell,Dragos Vinereanu,Keith A.A. Fox,Yan Liang,Lisheng Liu,Jun Zhu,Nana Pogosova,Aldo P. Maggioni,Alvaro Avezum,Leopoldo S. Piegas,Katalin Keltai,Matyas Keltai,Scott D. Berkowitz,Salim Yusuf

Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI Substudy.

2020

Background and Purpose: Covert brain infarcts are associated with cognitive decline. It is not known whether therapies that prevent symptomatic stroke prevent covert infarcts. COMPASS compared riva...

Keywords:

Aspirin
White matter
Rivaroxaban
Infarction
Stroke
Covert
Physical medicine and rehabilitation
Cognition
Medicine
cognitive decline

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations